Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy
Table 5
Comparison of plasma levels for the selected inflammatory molecules in subgroups of patients experiencing multiple symptoms (≥3) for intestinal acute/late toxicity. values for test are reported.
Acute toxicity
Late toxicity
Patients with <3 symptoms
Patients with ≥3 symptoms
t-test
Patients with <3 symptoms
Patients with ≥3 symptoms
t-test
Mean
SD
Mean
SD
Mean diff
Mean
SD
Mean
SD
Mean diff
CCL2 baseline
139.4
34.1
134.2
30.4
−5.2
0.75
145.5
37.3
124.9
16.5
−20.7
0.18
CCL2 50 Gy
155.7
33.9
159.7
40.9
4.1
0.83
162.4
38.5
152.3
36.7
−10.1
0.60
CCL2 end RT
161.2
20.7
165.8
42.4
4.6
0.79
165.5
39.1
161.6
28.1
−3.9
0.82
CCL2 1 mos
153.2
40.0
201.3
104.2
48.1
0.25
193.9
107.4
162.6
39.6
−31.3
0.46
IL-8 baseline
6.9
2.7
5.2
1.5
−1.7
0.15
6.4
2.6
5.4
1.6
−0.9
0.40
IL-8 50 Gy
6.6
2.5
5.4
1.9
−1.2
0.29
6.2
2.4
5.6
2.0
−0.6
0.60
IL-8 end RT
8.2
3.2
5.4
2.1
−2.8
0.06
7.6
3.1
5.4
2.3
−2.2
0.13
IL-8 1 mos
7.1
2.2
10.6
13.4
3.4
0.50
11.6
13.0
5.8
2.1
−5.8
0.25
PTX3 baseline
3.1
1.2
3.2
1.1
0.2
0.75
2.9
1.1
3.5
1.0
0.5
0.37
PTX3 50 Gy
3.3
1.5
3.1
1.1
−0.2
0.72
3.3
1.4
3.0
1.1
−0.3
0.69
PTX3 end RT
3.2
1.4
3.4
1.4
0.2
0.80
3.6
1.7
3.0
0.8
−0.6
0.40
PTX3 1 mos
3.2
1.3
3.0
1.2
−0.2
0.72
3.1
1.2
3.1
1.3
0.0
0.98
TNF alpha baseline
2.0
2.3
4.0
2.6
2.0
0.13
2.0
2.2
4.7
2.3
2.7
0.04
TNF alpha 50 Gy
2.1
2.5
3.6
3.0
1.5
0.29
2.0
2.4
4.0
3.1
2.0
0.17
TNF alpha end RT
1.9
2.3
3.3
2.4
1.3
0.27
1.9
2.2
3.7
2.3
1.8
0.14
TNF alpha 1 mos
2.3
2.3
3.8
2.3
1.5
0.23
2.5
2.6
4.1
1.8
1.6
0.17
^pg/ml for IL-1b, IL-6, CXCL8, CCL2, and TNF alpha; ng/ml: PTX3; SD: standard deviation; 1 mos: 1 month; RT: radiotherapy; diff: difference.
